July 25, 2005 -- Biotech moved progressively lower as the session wore on Monday, ending the day near its lows. The Centient Biotech 200 was off almost 32 points at 3671.64, a loss of .86%. Schering-Plough will assume sole marketing responsibility for Integrilin, taking over from Millennium; Incyte said its HIV medication was effective, but less so than observers expected; Teva bought Ivax for $26 a share in a $7.4 billion deal; Takeda won FDA approval for a sedative with a new mechanism; Forest Labs was denied the add-on indication of mild Alzheimer’s; and Cerus described its new mechanism for vaccines. More details...
